Abstract: Micro-droplet delivery devices and methods are described where the device may comprise a piezoelectric actuator having a piezoelectric chip that is operatively coupled to a drug package under a preloading force. The actuator is configured to generate an acoustic pressure within the drug package to dispense droplets of an agent from an aperture, e.g., to the corneal surface of the eye. The piezoelectric actuator can be coupled or decoupled from the drug package.

Abstract: An ophthalmic lens, comprising a central zone having at least a first power, and a peripheral zone having an add-power offset relative to the at least first power and a spatially-modulated optical parameter. In some embodiments, the central zone has a diameter in the range 2.0 to 5.0 mm. In some embodiments, the central zone is not more than 1 mm smaller than a wearer's pupil. The spatially-modulated optical parameter may include optical power, light scattering or light transmission.

Abstract: An ophthalmic surgical irrigation assembly for attachment to an ophthalmic surgical instrument. The assembly includes an elongated sleeve having a hollow interior space through which fluid is passed and surrounds a majority length of a cannula attached to the ophthalmic surgical instrument. A fluid port formed adjacent a distal end of the elongated sleeve allows the fluid to exit the interior space. A distal opening in the elongated sleeve allows a distal portion of the cannula to extend beyond the distal opening. A hub integrally formed with a proximal end of the elongated sleeve is adapted for fluid tight attachment to at least a portion of the surgical instrument and allows fluid to flow from the surgical instrument through the interior space and exit out of the fluid port. The elongated sleeve and the hub are each formed of a polyether block amide resin.

Abstract: An ophthalmically compatible solution includes (a) about 0.005 to about 2 wt. %, based on the total weight of the ophthalmically compatible solution, of hyaluronic acid or a salt thereof; (b) about 0.01 to about 1 wt. %, based on the total weight of the ophthalmically compatible solution, of erythritol; (c) sodium chloride, potassium chloride or any combination thereof; and (d) one or more buffers.

Abstract: Multi-dose preservative-free ocular fluid delivery devices are provided. The fluid delivery device includes a fluid dispensing system and a fluid package for storing a liquid therein and supplying said liquid to the dispensing system. The dispensing system comprises an elongated chamber which includes a check valve which defines a frontal closure to the chamber. The valve is normally closed and hermetically seals the chamber. The dispenser includes a vibration motor that induces oscillations to the chamber and to the fluid within. The oscillations of the chamber impart momentum to the fluid stored in the chamber which in turn imparts force that cyclically opens the valve to dispense streams or liquid droplets. Fluid is dispensed only when the motor oscillates while otherwise the valve is hermetically closed.

Abstract: Multi-dose preservative-free ocular fluid delivery devices are provided. The fluid delivery device includes a fluid dispensing system and a fluid package for storing a liquid therein and supplying said liquid to the dispensing system. The dispensing system comprises an elongated chamber which includes a check valve which defines a frontal closure to the chamber. The valve is normally closed and hermetically seals the chamber. The dispenser includes a vibration motor that induces oscillations to the chamber and to the fluid within. The oscillations of the chamber impart momentum to the fluid stored in the chamber which in turn imparts force that cyclically opens the valve to dispense streams or liquid droplets. Fluid is dispensed only when the motor oscillates while otherwise the valve is hermetically closed.

Abstract: A water extractable ophthalmic device is disclosed which is a polymerization product of a monomeric mixture comprising: (a) one or more cyclic lactams; (b) one or more non-bulky organosilicon-containing monomers; (c) one or more bulky siloxane monomers; and (d) a crosslinking agent mixture comprising (i) one or more first crosslinking agents containing at least two ethylenically unsaturated reactive end groups, wherein the at least two ethylenically unsaturated reactive end groups are (meth)acrylate-containing reactive end groups and (ii) one or more second crosslinking agents containing at least two ethylenically unsaturated reactive end groups wherein at least one of the ethylenically unsaturated reactive end groups is a non-(meth)acrylate reactive end group. The water extractable ophthalmic device has an equilibrium water content of at least about 50 wt. %, a contact angle of less than about 50°, and an oxygen permeability of at least about 60 Barrers.

Abstract: Ophthalmic compositions comprising an anti-allergen and a redness reduction agent, such as brimonidine or a pharmaceutically acceptable salt thereof, for treating itching and redness in a single composition. The ophthalmic compositions may be provided in a container closure system, such as a low density polyethylene bottle. Container closure systems and kits comprising the ophthalmic compositions are disclosed.

Abstract: An ophthalmic device for slowing, inhibiting or preventing myopia progression which is a polymerization product of a monomeric mixture comprising (a) greater than 50 wt. %, based on the total weight of the monomeric mixture, of one or more non-silicone-containing hydrophilic monomers; (b) one or more crosslinking agents; and (c) one or more red-light blocking compounds blocking greater than 5% to about 25% of red-light transmission through the ophthalmic device at a wavelength of from about 550 nm to about 800 nm, wherein the one or more red-light blocking compounds have one or more ethylenically unsaturated reactive end groups.

Abstract: A contact lens package, comprising blister packaging defining a cavity, a contact lens disposed in an unstressed state within the cavity, lens hydrating liquid partially filling the cavity, and lid stock sealed to the blister packaging such that a segment of the lid stock, in combination with the cavity, forms an enclosure of the lens and the liquid. The segment has an interior surface including at least one relief element. The interior surface exclusive of the at least one relief element is flat. An air gap is disposed between a top surface of the liquid and at least a portion of the interior surface. The at least one relief element on the interior surface of the lid stock may be formed while testing the structure for leaks by applying pressure to the lid stock with a stamp having a contour corresponding to the at least one relief element.

Abstract: A vitrectomy system includes a surgical cutting apparatus and a processor. The system includes a cutting assembly with an outer cutter and an inner cutter. The cutting assembly includes a housing containing a drive chamber, a spring chamber, at least a first diaphragm. The first diaphragm is adhered to the inner cutter and positioned between the drive chamber and the spring chamber. The system also includes a drive chamber valve to supply compressed air to the drive chamber and a spring chamber valve to adjust air pressure within the spring chamber. The processor is configured to pulse the drive chamber valve based on a desired cut rate to translate the inner cutter and adjust the air pressure within the spring chamber based on the desired cut rate to adjust the stiffness of the spring chamber.

Abstract: A packaging system for the storage of an ophthalmic device includes a sealed container containing one or more unused ophthalmic devices immersed in an aqueous packaging solution comprising one or more crosslinked polymeric networks. The one or more crosslinked polymeric network comprises a reaction product of a first glycosaminoglycan, a second glycosaminoglycan, and a first crosslinking agent, wherein the first glycosaminoglycan is different than the second glycosaminoglycan. The aqueous packaging solution has an osmolality of at least about 180 mOsm/kg, a pH of about 6 to about 9 and is heat sterilized.

Abstract: Methods for treating coronavirus disease 2019 (COVID-19), including at least one ocular manifestation of COVID-19, methods for treating conjunctivitis, and methods for reducing COVID-19 transmission comprising administering an effective amount of benzalkonium chloride are disclosed. Pharmaceutical compositions comprising benzalkonium chloride are also disclosed.

Abstract: A grafted glycosaminoglycan polymer is disclosed. The grafted glycosaminoglycan polymer comprises a glycosaminoglycan having a polymer backbone and one or more side chains comprising a polyalkylene glycol-containing residue grafted onto the polymer backbone.

Abstract: A contact lens package includes a first layer, a support coupled to the first layer, a lens, and a second layer. The support includes a scaffold and a porous member attached to the scaffold where the porous member includes a curved surface. The lens includes an anterior surface and a posterior surface, and the posterior surface of the lens is disposed on the curved surface of the porous member. The second layer is coupled to the first layer to seal the support and the lens between the first layer and the second layer.

Abstract: A phacoemulsification transducer assembly includes a reflector and a driver connected to the reflector. The driver has a known driver vibration frequency range. A horn is connected to the driver opposite the reflector. A needle is connected to the horn opposite the driver. The needle has a known free shaft length. To maximize a desired stroke length of the needle for a minimal amount of power applied to the driver, a material forming the needle is chosen such that a speed of sound through the material results in a quarter-wavelength distance at the driver vibration frequency range substantially equal to the needle free shaft length.

Abstract: A crosslinked polymeric network is disclosed. The crosslinked polymeric network comprises a reaction product of a first glycosaminoglycan, a second glycosaminoglycan, and a crosslinking agent, wherein the first glycosaminoglycan is different than the second glycosaminoglycan.

Abstract: An intraocular lens (IOL) injector is configured for single hand operation and employs a compressed gas to provide a motive force to present an IOL to a surgical site. The IOL injector includes a mechanical brake coupled to a plunger to preclude translation of an IOL absent operator input. The mechanical brake provides for selectively varying the speed and translation of the plunger, and hence IOL during presentation of the IOL to a patient. The IOL injector can also include at least a first stop, which halts movement of the plunger at a predetermined position. The at least first stop is then moved to a passing position, thereby allowing further operator controlled translation of the plunger to present the IOL to the surgical site.

Abstract: A biomedical device is disclosed which is a polymerization product of a mixture comprising (a) one or more difunctional isocyanates; (b) one or more polyalcohols; (c) one or more hydroxy-terminated polysiloxane prepolymers; and (d) one or more polyoxazoline polyols having a weight average molecular weight of equal to or greater than about 1000 Daltons.

Abstract: A glycophospholipid polymer is disclosed. The glycophospholipid polymer comprises a reaction product of one or more glycosaminoglycans and one or more phospholipids. Also disclosed is a glycophospholipid polymeric network comprising a reaction product of one or more glycosaminoglycans, one or more phospholipids and, one or more crosslinking agents.